The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 20, 2018
Filed:
Nov. 26, 2013
Applicant:
Katinger Gmbh, Vienna, AT;
Inventors:
Hermann Katinger, Vienna, AT;
Renate Kunert, Deutsch-Wagram, AT;
Thomas Sterovsky, Nodendorf, AT;
Thomas Hemetsberger, Klosterneuburg, AT;
Assignee:
KATINGER GMBH, , AT;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); C12N 5/10 (2006.01); C07K 16/30 (2006.01); G01N 33/577 (2006.01); C12N 15/13 (2006.01); C07K 16/34 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3084 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3053 (2013.01); G01N 33/577 (2013.01); C07K 2317/14 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/734 (2013.01); G01N 2800/7028 (2013.01);
Abstract
A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.